Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.89 USD
Change Today +0.13 / 4.71%
Volume 2.0M
OREX On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Michael A. Narachi M.S., M.B.A.

Chief Executive Officer, President and Director,Orexigen Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 21 board members in 3 different organizations across 6 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Michael A. Narachi, also known as Mike, M.S., M.B.A, has been the Chief Executive Officer and President of Orexigen Therapeutics, Inc. since March 2009. Mr. Narachi has more than 25 years of biotechnology and pharmaceutical experience in clinical development, commercialization, strategic business development and planning at Orexigen. He served as the Chief Executive Officer, Chairman and President of REN Pharmaceuticals Inc. He served as an Officer and Vice President ...

Read Full Background

Corporate Headquarters*

3344 North Torrey Pines Court
La Jolla, California 92037

United States

Phone: 858-875-8600
Fax: 858-875-8650

Board Members Memberships*

Chairman, Chairman of Compensation Committee, Member of Nominating & Corporate Governance Committee and Member of Audit Committee
Chief Executive Officer, President and Director
Independent Director, Member of Audit Committee and Member of Nominating & Corporate Governance Committee


University of California
BS 1984
University of California
UCLA Anderson School of Management

Other Affiliations*

Annual Compensation*

Total Annual Compensation$640,625

Stock Options*

All Other Compensation$8,816
Exercisable Options4,032,036
Unexercisable Options1,632,264
Total Number of Options5,664,300

Total Compensation*

Total Annual Cash Compensation$1,081,863
Total Short Term Compensation$640,625
Other Long Term Compensation$8,816
Total Calculated Compensation$4,499,269
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OREX:US $2.89 USD +0.13


Jack Lief Ph.D.Co-Founder, Chairman, Chief Executive Officer, President and Principal Financial Officer
Arena Pharmaceuticals, Inc.
Seth H. Z. Fischer Chief Executive Officer, Chief Commercial Officer and Director
Andrew Philip Witty Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee
GlaxoSmithKline plc
2.0M GBP
Lars Rebien Sørensen Chief Executive Officer, President and Member of Executive Management
Novo Nordisk A/S
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at